Organ Preservation in Muscle-Invasive Bladder Cancer
Organ Preservation in Muscle-Invasive Bladder Cancer
Organ preservation with nonextirpative
and frequently, chemotherapy
has become a favored strategy
in the treatment of cancers of the larynx,
esophagus, breast, soft-tissue extremity
sarcomas, and anal canal.
Bladder cancer is a more controversial
organ-preservation site due, in
part, to the biology of the tumor. Bladder
cancer can be multifocal, arising
from several areas of urothelium in
both the bladder and upper urinary
system. Herr et al reported a 21% rate
of upper urinary tract tumors in patients
with recurrent carcinoma in situ
and T1 bladder cancer treated with
transurethral resection of the bladder
tumor (TURBT) and bacillus Calmette-
Gurin (BCG) immunotherapy.[
1] In addition, there are concerns
that superficial recurrence after bladder
preservation may result in subsequent
invasive neoplasms and
The standard treatment for muscle-
invasive bladder cancer in the
United States is radical cystectomy
with a pelvic lymph node dissection.
The local control rate is excellent at
90%, but due to the development of
nonregional metastatic disease, the
5-year overall survival rate is only
about 50%. An alternative approach
is multimodality bladder preservation,
which in modern series
includes thorough TURBT, chemotherapy,
and radiation therapy. This
approach has been developed to improve
quality of life for patients who
want to maintain urinary function
without a diversion, and also for patients
who are not candidates for surgery.
Overall survival results from
large centers using the multimodality
conservative approach are similar to
those for radical cystectomy.[3-6]
This review will address issues
raised in a multimodality approach to
the treatment of invasive bladder cancer
including transurethral surgery,
neoadjuvant or adjuvant chemotherapy,
and radiation therapy.
of Bladder Tumor
Several studies have examined the
role of TURBT as a single modality
in the treatment of invasive bladder
cancer. A series of 308 patients by
Solsona et al reported a 5-year survival
rate of 83% and a bladder preservation
rate of 73%. In a carefully
selected group of patients, Herr et al
reported a similar bladder preservation
of 65% with an overall survival
rate of 70% in patients with T2 bladder
cancers. The majority of patients in
this trial required a repeat TURBT.
Although survival rates are acceptable,
local control with TURBT alone
may be compromised.
Complete TURBT is also the initial
step in the multimodality approach
to invasive bladder cancer. An aggressive resection is a crucial factor
in controlling local recurrence for patients
undergoing an organ-sparing
approach. In a University of Erlangen
series, patients were classified by completeness
of TURBT, with R0 indicating
no evidence of microscopic
tumor, R1 indicating a macroscopically
complete procedure with evidence
of microscopic disease, and R2
indicating a macroscopically incomplete
TURBT. Multivariate analysis
showed that R classification was
the only prognostic factor for both
local control and survival.
Patients who had macroscopic disease
after TURBT had a 5-year survival
of 31%, compared to 81% survival in
patients who had no evidence of microscopic
disease after TURBT. The
feasibility of a complete resection is
also dependent on the biology of the
tumor. A well circumscribed, superficial
tumor would likely be fully resected,
unlike a deeply invasive or widely
extensive bladder tumor.
Chemotherapy as a
Several studies have shown that
systemic chemotherapy alone has an
inferior local control rate, compared
to cystectomy, TURBT, and definitive
radiation therapy. Roberts et al
published a phase II study in locally
advanced bladder cancer treated with
cisplatin and methotrexate as primary
therapy. Response was seen in less
than half of patients, with partial response
in 34% and complete response
in only 11%. A study by Scher et al
showed that clinical response to chemotherapy
did not correspond to
pathologic response. While 56%
of patients achieved complete clinical
response with neoadjuvant M-VAC
(methotrexate, vinblastine, doxorubicin
[Adriamycin], cisplatin), residual
tumor was seen in 61% of cystectomy
specimens on pathology review. Another
study found a pathologic complete
response rate of 8.3% in 69
patients who received CMV (cisplatin, methotrexate, vinblastine) as primary
With such results, chemotherapy
is not currently used as a single modality
but instead as part of a multimodality
can work synergistically with radiation
to increase cell kill. The direct
cytotoxic effect of chemotherapy is
also important since up to 50% of
patients with muscle-invasive bladder
cancer have occult metastasis.
Radiation as a Single Modality
There are no randomized trials
directly comparing cystectomy to definitive
radiation therapy, but external-
beam irradiation has been used as
an alternative to cystectomy. Most
historical series of definitive radiation
therapy for muscle-invasive bladder
cancer included patients who
were medically unfit for cystectomy.
Gospodarowicz et al reported a 32%
overall survival at 5 years in 121 consecutive
patients who received definitive
radiation therapy. The initial
pelvic field received 35-40 Gy followed
by an additional 15-20 Gy to
the bladder. The cause-specific survival
in this study was 45%, with 27% of
patients maintaining functional bladders.
In a larger series of 963 patients
treated with radical photon radiotherapy
and 58 patients treated with radical
neutron radiotherapy reported by
Duncan and Quilty, 5-year overall survival
was similar at 36%.
Shipley et al found several positive
prognostic factors for choosing
patients for primary external-beam
therapy including clinical stage, no
evidence of hydronephrosis or obstruction,
complete TURBT, complete
response to radiotherapy at repeat cystoscopy,
and adequate radiation
dose. In this study, patients received
50.4 Gy in the bladder and
regional lymph nodes, followed by a
bladder boost to 14-18 Gy.
Several studies have compared immediate cystectomy to definitive external- beam radiation therapy with cystectomy only for incomplete response or failure. The only study to report a survival advantage with immediate cystectomy is a small series from M. D. Anderson. The 35 patients randomized to immediate cystectomy had a 5-year survival of 45%, whereas survival in delayed cystectomy patients was decreased to 22% at 5 years. Other studies have shown no difference in survival for delayed cystectomy, including the Urologic Cooperative Group study. In this series of 187 patients, 5- and 10-year survival rates in the cystectomy arm were 39% and 19%, compared to 28% and 15% for patients who had primary radiation therapy with cystectomy for incomplete response. The Danish National Bladder Cancer Group trial of 183 patients showed a statistically higher rate of pelvic recurrence in the radiation arm vs immediate cystectomy arm (35% vs 7%). However, these investigators found no difference in 5-year overall survival. Toxicity
Radiation therapy for bladder cancer has been associated with treatment toxicity. During treatment, approximately half of patients will report dysuria and urinary frequency, which resolves several weeks after radiation in most patients. Acute bowel toxicity occurs less frequently and is reported in approximately 15% of patients. The incidence of late bladder toxicity such as contracture was up to 45% in earlier series that used intravesical chemotherapy. With the current fraction size of 2 Gy or less and a total dose of 60 Gy to the bladder, late bladder toxicity occurs much less often. Shipley et al have reported less than a 1% rate of salvage cystectomy for bladder contraction or radiation cystitis. Multimodality Approach for Organ Preservation Several multimodality protocols have been conducted in the United States, with large series from Massachusetts General Hospital and cooperative groups such as the Radiation Therapy Oncology Group (RTOG). Most protocols start with TURBT of the bladder, with complete resection if possible. Then patients undergo concurrent radiation with chemotherapy. Certain chemotherapeutic agents, such as cisplatin and fluorouracil (5-FU), work as both cytotoxic agents and radiosensitizers. Several weeks after the induction phase, patients who are surgical candidates undergo a repeat cystoscopy with biopsy and cytology to determine response. Patients who have had a complete response undergo consolidation therapy with a combination of radiation and chemotherapy. Cystectomy is recommended for patients who have had an incomplete response. Early Trials
Initial evidence for the use of concurrent chemotherapy and irradiation came from precystectomy studies. A National Cancer Institute of Canada trial randomized patients to radiation alone vs radiation and cisplatin prior to planned cystectomy or planned definitive radiation. Investigators found a statistically higher rate of pelvic control in the patients who received chemotherapy at 58% vs 40% in the radiation-alone arm but no difference in distant metastasis or overall survival between the two groups. In a University of Paris study, patients underwent TURBT followed by radiation therapy to 24 Gy with concurrent cisplatin and 5-FU. Reevaluation with cystoscopy and biopsy revealed a 74% complete response rate. Patients with a complete response were randomized to cystectomy vs accelerated radiation and 5-FU and cisplatin. There was no difference in the survival of complete responders who had surgery vs continued chemotherapy and irradiation. However, disease-free survival at 3 years was significantly better in the responders (77%) vs nonresponders (23%). A study from Germany reported similar response and survival rates with induction therapy alone. The 184 patients in this study received platin-based chemotherapy with external- beam radiation to 45-54 Gy. Using cystoscopic evaluation, the complete response rate was 85% in patients receiving cisplatin and 70% in those receiving carboplatin (Paraplatin). The overall 5-year survival rate was 56%, with 41% survival in those with an intact bladder. RTOG Studies
The RTOG has been actively involved in bladder preservation protocols for patients with T2-4 tumors since 1985. A recent overview of these trials was published by Shipley et al (Table 1). The initial trial (RTOG 85-12) established the standard approach for subsequent trials. Patients received an induction radiotherapy dose of 40 Gy, with concurrent cisplatin. Patients who had a complete response, based upon cystoscopy, rebiopsy, and urine cytology, received an additional radiation dose to the bladder with further chemotherapy. The overall 4-year survival rate was 64%. RTOG 95-06 evaluated an accelerated radiation treatment with concurrent 5-FU and cisplatin, similar to the University of Paris regimen. This RTOG study included 34 patients who had a 67% complete response rate with induction therapy. The overall survival rate at 3 years was 83%. Current RTOG protocols are investigating the role of newer agents. RTOG 02-33 is a phase II study that randomizes patients to either cisplatin and 5-FU or cisplatin and paclitaxel with twice-daily radiation. After the complete responders have finished local therapy, all patients received adjuvant systemic therapy with gemcitabine (Gemzar), cisplatin, and paclitaxel. Other studies have looked at the role of neoadjuvant chemotherapy in the multimodality approach. RTOG 88-02 was the pilot study of two cycles of MCV (methotrexate, cisplatin, vinblastine) prior to concurrent chemotherapy and irradiation. The response rate was 75%, and 5-year survival rate was 51%. This led to the phase III trial RTOG 89-03, in which patients received either two cycles of neoadjuvant therapy with MCV followed by cisplatin and radiotherapy, or cisplatin and radiotherapy without the neoadjuvant MCV. Due to hematologic toxicities such as leukopenia and sepsis, this trial was stopped before the accrual goal was reached; nevertheless, 123 patients were accrued. There were no differences in overall survival, response rate, or rate of metastatic disease when the neoadjuvant group was compared to the standard-induction group. Meta-analysis
A meta-analysis of almost 2,700 patients from 10 randomized trials showed a small advantage in survival with neoadjuvant chemotherapy, although the difference was not statisfically significant when compared to other platinum-based chemotherapy regimens. The overall hazard ratio for patients receiving neoadjuvant chemotherapy was 0.91; ie, there is a 9% relative reduction in risk of death associated with neoadjuvant chemotherapy. Overall survival increased from 45% to 48% in this group, but the difference was not significant (P = .08). Patients who received platinum- based combination chemotherapy showed a 13% decrease in risk of death and a statistically significant improvement in overall survival (from 45% to 50%). This improvement was present regardless of whether local treatment consisted of cystectomy, radiation therapy, or both. Quality of Life With Organ Preservation One of the main goals of bladder preservation is to improve quality of life by preserving a functional bladder and avoiding the need for a urinary diversion. Multimodality therapy can affect organs beyond the bladder including the rectum, small bowel, anal sphincter, and the nerves and vessels that control sexual functioning. A series by Henningsohn et al reported the results from 71 patients in Stockholm treated with radiation therapy between 1977 and 1995. The radiation dose ranged from 58-63 Gy. These patients were compared to 460 age-matched controls as well as 250 patients who underwent cystectomy. Through anonymous questionnaires, 74% of irradiated patients reported little or no distress from urinary symptoms and 68% were free of moderate or severe gastrointestinal symptoms. Compared to cystectomy patients, more irradiated patients retained sexual function. Based on the survey, 38% of irradiated patients had intercourse in the previous month compared to 13% of cystectomy patients. The 75% of patients who retained a functioning urinary bladder after radiotherapy in this series is similar to findings in other multimodality series (Table 2). Rates of salvage cystectomy for bladder contracture or radiation cystitis from recent multimodality protocols are 1% or less. Two recent abstracts addressing quality of life after organ preservation for muscle-invasive bladder cancer were presented at American Society for Therapeutic Radiation and Oncology (ASTRO) meeting. The first is a French study that assessed 53 patients treated with concurrent chemotherapy and radiation therapy between 1999 and 2001. With a median follow-up of 2 years, 82% of patients had preserved bladders. Approximately 67% of patients with a preserved bladder reported satisfactory urinary function at 2 years. Zietman et al presented bladder preservation results from Massachusetts General Hospital using both quality- of-life questionnaires and formal urodynamic studies. On urodynamic evaluation, 80% of patients (19/26) had normal bladder function. The quality-of-life questionnaire revealed no significant urinary symptoms in over 80% of patients. The incidence of bowel dysfunction was low, and 55% of men reported sufficient erection for intercourse within the month prior to the survey. Superficial Recurrence in Organ Preservation After undergoing bladder preservation, patients must undergo careful surveillance because they are at risk for developing both invasive and superficial recurrences. If a muscleinvasive recurrence develops, salvage cystectomy is recommended. However, there is more debate on how to manage superficial recurrences. Between 9% and 28% of patients who undergo bladder preservation will have a superficial relapse. While a conservative approach-ie, reresection with TURBT and intravesical therapy-can be taken, there is concern that aggressive lesions may become invasive. Several studies have looked at the prognosis of superficial recurrence and its impact on survival. Zietman et al studied 190 consecutive patients enrolled in bladder preservation protocols at Massachusetts General Hospital between 1986 and 1998. The complete response rate in this group was 64% when reevaluation cystoscopy was performed; those who did not have a complete response were advised to undergo a cystectomy. The 5-year disease-specific survival rate was 63% for the entire group. Thirty-two patients (26%) had a superficial recurrence with a median time to failure of 2.1 years, and 28 of these patients were managed conservatively with intravesical BCG, TURBT, or a combination of the two. Of these patients, 64% had no further recurrence. The majority (67%) of recurrences in this study were in the same region as the original tumor. There was no difference in 5-year survival between patients who had superficial recurrence (69%) and those who did not (68%). However, there was a statistically significant difference in survival with an intact bladder: Among patients without a recurrence, 61% were alive with an intact bladder vs 34% of patients with a recurrence. Another study that examined superficial relapses after bladder preservation was published by Pieras et al. A select group of 51 patients underwent a transurethral resection followed by three cycles of carboplatin and vinblastine; no radiation therapy was given. A total of 42 patients responded to treatment on cystoscopy 3 weeks after finishing treatment and proceeded with bladder preservation. Eighteen patients (43%) experienced superficial recurrences at a mean of 19 months; median follow-up in this study was 5 years. There was no statistically significant difference in cancer-specific survival among patients who were recurrencefree (89%) vs those with a superficial recurrence (94%). Unlike the prior study, 66% of recurrences were at a different site than that of the initial tumor. There was also no significant difference in rates of bladder preservation when comparing patients who had a superficial recurrence (83%) to those who did not (78%) in this study. The authors concluded that superficial recurrences could be treated conservatively without compromising survival. Conclusions Multimodality bladder preservation protocols have produced survival rates similar to those achieved with radical cystectomy. Survival rates are directly related to the clinical stage of the tumor. In a series of 190 patients enrolled in a bladder-preservation protocol, 66 underwent cystectomy for either incomplete response or recurrence.[ 6] The overall survival for patients with T2 tumors at 5 and 10 years was 62% and 41%. The 5- and 10-year survival rates dropped to 47% and 31% for patients with T3-T4a tumors. Survival with an intact bladder at 10 years also dropped with stage, from 50% in T2 patients to 34% in T3-4a patients. Given that many patients would be candidates for neobladder formation with continent diversions, quality-oflife issues are raised with multimodality therapy. Additional quality-oflife data are becoming available, but thus far, urinary, bowel, and sexual functioning after bladder preservation seem acceptable. Moreover, the rates of cystectomy for bladder contracture or cystitis after multimodality treatment are extremely low. After bladder preservation, patients are at risk for both superficial and invasive recurrence. The ideal candidate for this approach would be compliant with the frequent follow-up necessary to evaluate disease status. Evidence from multiple studies does not support decreased survival with immediate cystectomy vs delayed cystectomy for recurrence. Patients with superficial recurrence also have no difference in cancer-specific survival when compared to those who show no evidence of recurrence. However, there are conflicting data regarding survival with an intact bladder after superficial recurrence. When examining these issues on the basis of available data, bladder preservation with multimodality treatment is a viable option for patients with muscle-invasive bladder cancer. For patients who are alive at 5 years, 80% have an intact bladder. Current protocols incorporate chemotherapeutic agents such as docetaxel (Taxotere) and gemcitabine to improve efficacy without increasing toxicity. Various radiation fractionation schedules such as hypofractionation and twice-daily treatments are also being evaluated in current protocols. Evidence supports careful selection of patients for bladder preservation including those who have a complete TURBT, no evidence of ureteral obstruction, complete response to induction chemotherapy and radiation therapy, and T2 tumors. Lastly, this approach requires dedicated multidisciplinary teams so that patients receive effective initial treatment and close follow-up.
2. Waehre H, Ous S, Klevmak B, et al: A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer 72:3044-3051, 1993.
3. Houseset M, Maulard C, Chretien Y, et al: Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: A prospective study. J Clin Oncol 1:2150- 2157, 1993.
4. Sauer R, Birkenhake S, Kuhn R, et al: Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 40:121-127, 1998.
5. Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy and Oncology Group 89-03. J Clin Oncol 16:3576-3583, 1998.
6. Shipley WU, Kaufman DS, Zehr E, et al: Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 60:62-68, 2002.
7. Solsana E, Iberra I, Ricos JV, et al: Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: Prospective study. J Urol 147:1513-1515, 1992.
8. Herr HW: Conservative management of muscle infiltrating bladder cancer: Prospective experience. J Urol 138:1162-1163, 1987.
9. Dunst J, Sauer R, Schrott M, et al: Organsparing treatment of advanced bladder cancer: A 10 year experience. Int J Radiat Oncol Biol Phys 30:261-266, 1994.
10. Dunst J, Rodel C, Zieman A, et al: Bladder preservation in muscle invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol 20:24-32, 2001.
11. Roberts J, Fossa S, Richards B et al: Results of Medical Research Council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder. Br J Urol 68:162-168, 1991.
12. Scher HI, Yagoda A, Herr HW, et al: Neoadjuvant M-VAC effect on the primary bladder lesion. J Urol 139:470-474, 1988.
13. Scattoni V, Pozzo L, Nava L, et al: Five year results of neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer. Eur Urol 28:102-107, 1995.
14. Gospodarowicz M, Hawkins G, Rawlings J, et al: Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis. J Urol 142:1448-1453, 1989.
15. Duncan W, Quilty PM: The results of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage x-ray therapy. Radiother Oncol 7:299-310, 1986.
16. Shipley WU, Rose MA: Bladder cancer: The selection of patients for treatment by full dose irradiation. Cancer 55:2278-2284, 1985.
17. Miller LS: Bladder cancer: Superiority of preoperative radiation in cystectomy in clinical stage B2 and C. Cancer 39:973-980, 1977.
18. Horwich A, Pendlebur S, Dearnaley D: Organ conservation in bladder cancer. Eur J Cancer 31(suppl 6):208-209, 1995.
19. Sell A, Jakobsen A, Nerstrom B, et al: Treatment of advanced bladder cancer category T2, T3, T4a. A randomized multicenter study of preoperative radition and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. Scand J Urol Nephrol (suppl 138):193-201, 1991.
20. Salminen E: Recurrence and treatment of urinary bladder cancer after failure in radiotherapy. Cancer 66:2341-2345, 1990.
21. Coppin CM, Gospodarowicz MK, James K, et al: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14:2901-2907, 1996.
22. Shipley WU, Kaufman DS, Tester WJ, et al: Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 97(suppl 8):2115-2119, 2003.
23. Tester W, Porter A, Asbell S, et al: Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG 85-12. Int J Radiat Oncol Biol Phys 25:783-790, 1993.
24. Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-FU followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5:471-476, 2000.
25. Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of RTOG phase III trial 8802. J Clin Oncol 14:119-126, 1996.
26. Advanced Bladder Cancer Meta-analysis collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: A systemic review and meta-analysis. Lancet 361:1927-1934, 2003.
27. Henningsohn L, Wijstrom H, Dickman P, et al: Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 22:111-117, 1991.
28. Michaelson D, Zietman A: Invasive bladder cancer: The role of bladder-preserving therapy. American Society of Clinical Oncology 2003 Educational Book, pp 457-465. 39th ASCO Annual Meeting, Chicago, May 31-June 3, 2003.
29. Cauvet B, Lagrange JL, Geoffrois L, et al: Quality of life assessment after concurrent chemoradiation for invasive bladder cancer. Preliminary results of a French multicenter prospective study. Int J Radiat Oncol Biol Phys 57(suppl):177, 2003.
30. Zietman AL, Sacco DE, Skowronki UE, et al: Organ conservation as an alternative to radical cystectomy for invasive bladder cancer: Urodynamic and quality of life evaluation of patients treated by trimodality therapy. Int J Radiat Oncol Biol Phys 54(suppl):62, 2002.
31. Zietman AL, Shipley WU, Kaufman DS, et al: Organ conserving approaches to muscle invasive bladder cancer: Future alternatives to radical cystectomy. Ann Med 32:34-42, 2000.
32. Zietman AL, Grocela J, Zehr E, et al: Selective bladder conservation using transurethral resection, chemotherapy, and radiation: Management and consequences of Ta, T1 and Tis recurrence within the retained bladder. Urology 58:380-385, 2001.
33. Pieras E, Palou J, Salvador J, et al: Management and prognosis of transitional cell carcinoma. Superficial recurrence in muscle invasive bladder cancer after bladder preservation. Eur Urol 44:222-225, 2003.